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Objective. Systemic sclerosis (SSc) is associated with interstitial lung disease (ILD) and pulmonary hypertension 
(PH). This study was undertaken to determine the prevalence, characteristics, treatment, and outcomes of PH in a 
cohort of patients with SSc- associated ILD.
Methods. Patients with SSc- associated ILD on high- resolution computed tomography (HRCT) were included in a 
prospective observational cohort. Patients were screened for PH based on a standardized screening algorithm and 
underwent right- sided heart catheterization (RHC) if indicated. PH classification was based on hemodynamic findings 
and the extent of ILD on HRCT. Summary statistics and survival using the Kaplan- Meier method were calculated.
Results. Of the 93 patients with SSc- associated ILD included in the study, 76% were women and 65.6% had 
diffuse cutaneous SSc. The mean age was 54.9 years, and the mean SSc disease duration was 8 years. Twenty- nine 
patients (31.2%) had RHC- proven PH; of those 29 patients, 24.1% had PAH, 55.2% had World Health Organization 
(WHO) Group III PH, 34.5% had WHO Group III PH with pulmonary vascular resistance >3.0 Wood units, 48.3% had 
a PH diagnosis within 7 years of SSc onset, 82.8% received therapy for ILD, and 82.8% received therapy for PAH. 
The survival rate 3 years after SSc- associated ILD diagnosis for all patients was 97%. The survival rate 3 years after 
PH diagnosis for those with SSc- associated ILD and PH was 91%.
Conclusion. In a large cohort of patients with SSc- associated ILD, a significant proportion of patients had 
 coexisting PH, which often occurs early after SSc diagnosis. Most patients were treated with ILD and PAH therapies, 
and survival was good. Patients with SSc- associated ILD should be evaluated for coexisting PH.
INTRODUCTION
Systemic sclerosis (SSc) can be a devastating multiorgan 
system autoimmune disease. It can affect the skin, peripheral vas-
culature, muscles, joints, tendons, kidneys, gastrointestinal tract, 
lungs, and heart through fibrosis, vascular damage, and immune 
dysregulation. Interstitial lung disease (ILD) and pulmonary arterial 
hypertension (PAH) are the leading causes of mortality in SSc (1,2).
Up to 90% of patients with SSc have ILD on high- resolution 
computed tomography (HRCT), and ~40% of patients with SSc 
have clinically significant ILD (3,4). Pulmonary hypertension (PH) is 
also common in SSc, and patients with SSc can have various types 
of PH. Three common types of PH in patients with SSc include 
World Health Organization (WHO) Group I PH (PAH), WHO Group 
II PH (PH due to left- sided heart disease), and WHO Group III PH 
(PH due to ILD). However, in observational cohorts of SSc, which 
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are enriched for patients at risk of or with early PH, the majority of 
patients are diagnosed as having PAH and a smaller proportion 
are classified as having WHO Group II PH or WHO Group III PH 
(5,6). For example, in the Pulmonary Hypertension Assessment 
and Recognition of Outcomes in Scleroderma (PHAROS) study, 
~69% of the patients with PH were classified as having PAH, 10% 
of the patients were classified as having WHO Group II PH, and 
21% of the patients were classified as having WHO Group III PH 
(5). In the DETECT study, which recruited patients at high risk of 
PH, ~60% of the patients with PH were classified as having PAH, 
21% were classified as having WHO Group II PH, and 19% were 
classified as having WHO Group III PH (6).
Although previous studies have analyzed patients with con-
comitant SSc- associated ILD and PH, to our knowledge there is 
a lack of in- depth review of the clinical characteristics and man-
agement of PH in patients with established SSc- associated ILD. 
This is an essential clinical question, since worsening dyspnea in 
a patient with underlying ILD may represent progressive ILD, new- 
onset PH, or a combination of both. In addition, many ongoing 
clinical trials are specifically recruiting patients with SSc- associated 
ILD, particularly for the evaluation of new and existing pharmaco-
logic therapies for the treatment of ILD. Hence, it is imperative 
to recognize the prevalence of PH with concomitant ILD in SSc 
and its impact on the clinical course, outcome measures, such as 
dyspnea and quality of life, and survival. This need prompted us to 
investigate the prevalence of PH in a well- characterized cohort of 
patients with SSc- associated ILD, and to explore the clinical char-
acteristics, pharmacologic therapies, and outcomes of patients 
with PH in that cohort.
PATIENTS AND METHODS
Study design and patients. Patients evaluated in this 
study were participants in a prospective observational cohort 
study of SSc- associated ILD (Figure 1). Patients were recruited 
from the University of Michigan Scleroderma and Connective 
Tissue Disease (CTD)–ILD clinics starting January 8, 2014, and 
data were extracted on October 1, 2016. Patients who were at 
least 18 years of age, met the 2013 American College of Rheu-
matology/European League Against Rheumatism classification 
criteria for SSc (7), had ILD on HRCT, and could provide informed 
consent were included in the study, which was approved by the 
University of Michigan Institutional Review Board. All reported 
experiments performed by the authors have been previously 
published and complied with all applicable ethical standards 
(including the Declaration of Helsinki and its amendments, insti-
tutional/national research committee standards, and interna-
tional/national/institutional guidelines).
All patients in this study had a baseline HRCT confirming the 
presence of ILD, defined as the presence of bilateral, subpleural, 
lower lobe predominant distribution of either 1) reticular and/or 
ground- glass opacity with or without traction  bronchiectasis or 
2) honeycombing with the absence of a pattern that is predomi-
nantly nodular, cystic, peribronchovascular/central or upper lung 
predominant, mosaic attenuation, or consolidation. Pulmonary 
function tests (PFTs) were performed at baseline for each patient. 
Patients with a forced expiratory volume in 1 second/forced vital 
capacity (FVC) ratio of <0.7 were excluded to rule out patients 
with concomitant obstructive pulmonary disease. Demographic 
characteristics and additional clinical variables were obtained for 
each patient.
All patients in the University of Michigan Scleroderma 
and CTD- ILD clinics undergo screening for PH based on the 
2013 recommendations for screening and detection of CTD- 
associated PAH by Khanna et al, which also include the DETECT 
algorithm (8). Although the DETECT algorithm has been vali-
dated in patients with a disease duration of >3 years and diffus-
ing capacity for carbon monoxide (DLco) <60%, we use it for all 
SSc patients with uncorrected DLco ≤80% (6). We performed 
a chart review for all patients in this SSc- associated ILD cohort 
to determine which patients fulfilled criteria indicating possible 
PH based on the 2013 recommendations and had undergone 
right- sided heart catheterization (RHC) during their SSc dis-
ease course. Within this SSc- associated ILD cohort, the 2013 
recommendations were prospectively applied to 81 patients 
during routine clinical care (Supplementary Table 1, available 
on the Arthritis & Rheumatology web site at http://onlin elibr ary.
wiley.com/doi/10.1002/art.40862/ abstract) and retrospectively 
applied to 12 patients who had undergone RHC prior to 2013 
(Supplementary Table 2, available on the Arthritis & Rheuma-
tology web site at http://onlin elibr ary.wiley.com/doi/10.1002/
art.40862/ abstract) (8).
A total of 53 patients in the cohort had undergone RHC. 
Patients who had PH on RHC, which was defined as a mean pul-
monary artery pressure (PAP) of ≥25 mm Hg, are referred to herein 
as patients with “SSc- associated ILD and PH,” and patients who 
did not meet the 2013 recommendations or had a mean PAP 
of <25 mm Hg on RHC are referred to herein as patients with 
“SSc- associated ILD without PH.” For those with SSc- associated 
ILD and PH, the HRCT scan was reviewed by a chest radiolo-
gist (DV) to determine ILD severity. ILD severity was based on 
Goh’s criteria, in which <20% extent of ILD on HRCT was consid-
ered minimal and >20% extent of ILD on HRCT was considered 
moderate-to-severe (9,10). The HRCT scans chosen for review 
were the scans obtained closest to the time of diagnosis of RHC. 
(One patient’s HRCT images were not available for review, so a 
CT angiogram was reviewed, and another patient did not have 
any images available at our institution for review, so ILD type and 
severity were based on an external radiologist’s initial report.)
Classification of PH. Patients classified as having WHO 
Group I PH/PAH had a mean PAP of ≥25 mm Hg, pulmonary 
capillary wedge pressure (PCWP) ≤15 mm Hg, and <20% extent 
of ILD on HRCT (10–12). Patients classified as having WHO Group 
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II PH had a mean PAP of ≥25 mm Hg and PCWP >15 mm Hg. 
Patients classified as having WHO Group III PH had a mean PAP 
of ≥25 mm Hg, PCWP ≤15 mm Hg, and >20% extent of ILD 
on HRCT (10–12). Of the patients with WHO Group III PH, those 
with a mean PAP of ≥35 mm Hg were further classified as having 
severe PH based on the recommendations of Seeger et al (13) 
(Figure 1).
Statistical analysis. Descriptive statistics for the overall 
SSc- associated ILD cohort, patients with SSc- associated ILD 
without PH, and patients with SSc- associated ILD and PH were 
calculated for demographic and clinical characteristics using the 
mean ± SD for continuous variables and percentage for categor-
ical variables. The differences between the group without PH and 
the group with PH were compared using Student’s t- test for con-
tinuous variables and the chi- square test for categorical variables.
The Kaplan- Meier method was used to evaluate time until 
patient death in the overall SSc- associated ILD cohort and in the 
subset of those with SSc- associated ILD and PH, or censored 
at October 1, 2016. The log rank test was used to determine if 
there was a statistically significant difference in survival time in 
patients with SSc- associated ILD and PH versus those with SSc- 
associated ILD without PH. Cox proportional hazards regression 
was used to determine if race (non- Hispanic white versus non-
white) and age predicted survival in both subsets.
To evaluate whether there was a significant trend over 
time in FVC and DLco for the PFT findings obtained in the 
prospective observational cohort, a linear mixed- effects model 
Figure 1. Study design and characterization of pulmonary hypertension (PH) in a cohort of patients with systemic sclerosis (SSc)–associated 
interstitial lung disease (ILD). * Of the 14 patients who did not undergo right- sided heart catheterization (RHC), 7 were referred to cardiology but 
did not undergo RHC since there was a low likelihood of PH based on evidence, 2 refused RHC, 1 was lost to follow- up, 2 had negative findings 
on RHC after data analysis, 1 had normailization of transthoracic echocardiography (TTE) findings, and 1 had stable lower diffusing capacity for 
carbon monoxide (DLco), normal N- terminal pro–brain natriuretic peptide levels, and no pulmonary arterial hypertension (PAH) findings on TTE. 
† Of the 3 patients without signs/symptoms for RHC who underwent RHC, 2 underwent RHC due to severe symptoms and had negative RHC 
findings, and 1 underwent RHC due to a decline in DLco and had World Health Organization (WHO) Group III PH; the data needed to calculate 
DETECT scores were not available for any of these patients. ‡ Of the 3 patients with WHO Group II PH with >20% extent of ILD, 1 also had 
combined postcapillary and precapillary PH according to the guidelines by Vachiery et al (16) (pulmonary capillary wedge pressure [PCWP] >15 
mm Hg and diastolic pulmonary artery pressure [PAP] − PCWP ≥7 mm Hg) and had features of chronic thromboembolic disease based on 
pulmonary artery angiography. § Patients with severe PH had SSc- associated ILD with PH due to ILD with a mean PAP (mPAP) of ≥35 mm Hg 
on RHC according to the criteria by Seeger et al (13). CTD = connective tissue disease; PVR = pulmonary vascular resistance; WU = Wood units.
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ILD and PH 
(n = 29) P
Age at initial non- RP sign/symptom, years 46.9 ± 13.3 45.2 ± 13.2 50.9 ± 12.8 0.054
Age at ILD diagnosis, years 51.6 ± 12.2 49.7 ± 11.8 55.8 ± 12.1 0.02
Age at study enrollment, years 54.9 ± 11.5 52.9 ± 11.4 59.3 ± 10.6 0.01
Sex, no. (%) women 71 (76.3) 47 (73.4) 24 (82.8) 0.33
Race, no. (%) 0.02
White 79 (84.9) 57 (89.1) 22 (75.9)
African American 8 (8.6) 2 (3.1) 6 (20.7)
Asian/Asian American 3 (3.2) 3 (4.7) 0
Native American/Alaska Native 1 (1.1) 0 1 (3.4)
Other 2 (2.2) 2 (3.1) 0
Ethnicity, no. (%) 0.51
Hispanic 9 (9.7) 7 (10.9) 2 (6.9)
Non- Hispanic 82 (88.2) 55 (85.9) 27 (93.1)
Other 2 (2.2) 2 (3.1) 0
SSc subtype, no. (%) 0.34
dcSSc 61 (65.6) 44 (68.8) 17 (58.6)
lcSSc 32 (34.4) 20 (31.3) 12 (41.4)
Disease duration
Time from initial non- RP sign/symptom to study 
enrollment, years
7.9 ± 7.2 7.7 ± 7.6 8.5 ± 6.1 0.65
Time from initial non- RP sign/symptom to ILD 
diagnosis, years
4.7 ± 6.4 4.6 ± 6.9 4.9 ± 5.4 0.80
Time from ILD diagnosis to study enrollment, 
years
3.2 ± 3.6 3.2 ± 3.2 3.5 ± 4.3 0.65
ILD duration, years 4.7 ± 3.6 4.6 ± 3.2 4.8 ± 4.3 0.74
MRSS (at enrollment) (n = 89) 9.4 ± 9.5 9.9 ± 9.8 8.4 ± 8.9 0.51
Autoantibodies, no. (%)
ANA positivity (n = 86) 79 (91.9) 57 (95) 22 (84.6) 0.19
ANA pattern (n = 76) 0.10
Nucleolar 11 (14.5) 9 (16.4) 2 (9.5)
Centromere 6 (7.9) 2 (3.6) 4 (19)
Other† 59 (77.6) 44 (80) 15 (71.4)
Scl- 70 positivity (n = 85) 24 (28.2) 20 (33.3) 4 (16) 0.12
RNA polymerase III positivity (n = 51) 11 (21.6) 9 (25.7) 2 (12.5) 0.47
PM/Scl positivity (n = 35) 2 (5.7) 1 (4.2) 1 (9.1) 0.54
ILD (on HRCT), no. (%) 0.13
Nonspecific interstitial pneumonia 84 (90.3) 60 (93.8) 24 (82.8)
Usual interstitial pneumonia 9 (9.7) 4 (6.3) 5 (17.2)
PFTs (obtained closest to the ILD diagnosis date)
FVC, % predicted (n = 93) 76.2 ± 15.7 77.2 ± 14.3 73.9 ± 18.5 0.35
TLC, % predicted (n = 66) 83 ± 16.3 85.0 ± 14.8 78.7 ± 18.8 0.14
DLco, % predicted (n = 85) 58.3 ± 20.3 63.4 ± 20.1 46.8 ± 15.6 <0.001
FVC, % predicted/DLco, % predicted (n = 85) 1.5 ± 0.8 1.3 ± 0.5 1.9 ± 1.2 0.007
(Continued)
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with a fixed effect for time (continuous, in months) and a ran-
dom effect for the patient was used to predict change from 
baseline for both FVC and DLco. All analyses were performed 
using SAS software version 9.4. P values less than 0.05 were 
considered significant.
RESULTS
Baseline characteristics of the total cohort. A total of 
93 patients with SSc- associated ILD were evaluated in this study. 
The mean ± SD time from ILD diagnosis to study enrollment 
was 3.2 ± 3.6 years. Most patients were white (84.9%), female 
(76.3%), non- Hispanic (88.2%), and had diffuse cutaneous SSc 
(dcSSc) (65.6%). The mean ± SD overall SSc disease duration 
from initial non- Raynaud’s phenomenon (RP) sign/symptom for 
the entire cohort was 7.9 ± 7.2 years, and the mean ± SD time 
to diagnosis of ILD after initial non- RP sign/symptom was 4.7 
± 6.4 years. The mean ± SD modified Rodnan skin thickness 
score was 9.4 ± 9.5. The most common ILD pattern on HRCT 
was nonspecific interstitial pneumonia (NSIP; 90.3%). PFTs at 
ILD diagnosis revealed an FVC % predicted of 76.2 ± 15.7, 
total lung capacity (TLC) % predicted of 83.0 ± 16.3 (n = 66), 
DLco % predicted of 58.3 ± 20.3 (n = 85) (4 patients had DLco 
assessment attempted without success, 2 patients were ill, and 
2 patients did not have DLco ordered with PFTs at the time of ILD 
diagnosis), and a ratio of FVC % predicted to DLco % predicted 
of 1.5 ± 0.8 (n = 85) (Table 1).
The mean ± SD study duration for patients within this 
SSc- associated ILD cohort was 16.6 ± 4.3 months. At the 
time of data analysis, 12 patients were considered lost to fol-
low- up since they had not followed up in clinic for >12 months, 
2 patients had withdrawn consent, and 3 patients had died. 
There was a significant trend over time for both FVC and DLco 
after ILD diagnosis in all 93 patients with SSc- associated ILD 
in this cohort. Each year after ILD diagnosis, FVC was reduced 
by a mean ± SEM of 1.23 ± 0.14% and DLco was reduced by 
a mean ± SEM of 1.22 ± 0.18%. However, there was no signif-
icant change in FVC or DLco from study enrollment for any of 
the 93 patients in the cohort.
Prevalence of SSc- associated ILD and PH and 
 baseline characteristics of the patients. Twenty- nine 
patients (31.2%) in this SSc- associated ILD cohort had RHC- 
proven PH, referred to herein as the subgroup with “SSc- 
associated ILD and PH.” The mean ± SD time from initial non- RP 
signs/symptoms to PH diagnosis was 7.0 ± 5.5 years, and 
75.9% of the patients with PH (22 of 29) had PH diagnosed 
prior to enrollment in the ILD cohort. Thirty- one percent of the 
patients with SSc- associated ILD and PH (9 of 29) were diag-
nosed as having PH prior to the development of the 2013 rec-
ommendations for screening and detection of CTD- associated 
PAH, 65.5% of the patients with SSc- associated ILD and PH 
(19 of 29) were at risk for PH according to the 2013 recommen-
dations, and 1 patient with SSc- associated ILD and PH did not 
have signs/symptoms indicating a need for RHC based on the 
2013 recommendations but underwent RHC due to progressive 
symptoms and declining DLco.
The remaining 64 patients with SSc- associated ILD are 
referred to herein as patients with “SSc- associated ILD without 
PH.” Twenty- four patients had negative findings on RHC. The 
remaining 40 patients did not have signs/symptoms to proceed 









ILD and PH 
(n = 29) P
TTE‡
RV function, no. (%) (n = 92) <0.001
Normal 84 (91.3) 62 (98.4) 22 (75.9)
Abnormal 8 (8.7) 1 (1.6) 7 (24.1)
RV enlargement, no. (%) 0.02
No 80 (86.0) 59 (92.2) 21 (72.4)
Yes 13 (14.0) 5 (7.8) 8 (27.6)
RVSP, mm Hg (n = 63)§ 37.8 ± 19.6 30.9 ± 8.2 49 ± 26.7 <0.001
* Except where indicated otherwise, values are the mean ± SD. SSc = systemic sclerosis; ILD = interstitial lung disease; 
PH = pulmonary hypertension; RP = Raynaud’s phenomenon; dcSSc = diffuse cutaneous SSc; lcSSc = limited cutaneous SSc; 
MRSS = modified Rodnan skin thickness score; HRCT = high- resolution computed tomography; PFTs = pulmonary function tests; 
FVC = forced vital capacity; TLC = total lung capacity; DLco = diffusing capacity for carbon monoxide; RV = right ventricular; RVSP 
= right ventricular systolic pressure. 
† Antinuclear antibody (ANA) positivity indicated by any immunofluorescence pattern other than nucleolar or centromere. 
‡ Transthoracic echocardiography (TTE) data were captured after enrollment in the cohort. 
§ No tricuspid regurgitation jet was observed in 30 patients. 
Table 1. (Cont’d)
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ommendations by Khanna et al (n = 26), were believed by a PH 
expert to have a low likelihood of PH based on available evidence 
(n = 7), had a pending RHC at the time of data analysis (n = 2), 
refused RHC (n = 2), were lost to cardiology follow- up (n = 1), had 
normalization of previously abnormal transthoracic echocardiog-
raphy (TTE) findings (n = 1), or had stability of lower DLco in the 
setting of normal N- terminal pro–brain natriuretic peptide levels 
and normal TTE findings (n = 1) (Figure 1). When compared to 
patients with SSc- associated ILD without PH, patients with SSc- 
associated ILD and PH were older at ILD diagnosis (mean age 
55.8 years versus 49.7 years; P = 0.02), were more likely to be Afri-
can American (20.7% versus 3.1%, P = 0.02), had lower DLco % 
predicted (46.8% versus 63.4%; P < 0.001) and had a higher 
ratio of FVC % predicted to DLco % predicted (1.9 versus 1.3; 
P = 0.007) at ILD diagnosis (Table 1).
Analysis of the time to diagnosis of PH after the initial non- RP 
sign/symptom showed that 37.9%, 44.8%, and 48.3% of the 
patients had a diagnosis of PH within 3, 5, and 7 years, respec-
tively. We also performed analyses to evaluate baseline character-
istics, cardiopulmonary characteristics, treatments, and outcomes 
for those with PH diagnosed <7 years (n = 14) compared to ≥7 
years (n = 15) after the initial non- RP sign/symptom, which was 
based on the inclusion of patients with a disease duration of <7 
years from initial non- RP sign/symptom in recent SSc- associated 
ILD clinical trials (14,15). There were no significant differences 
between patients with early diagnosis of PH (<7 years from ini-
tial non- RP symptom) and patients with late diagnosis of PH (≥7 
years from initial non- RP symptom) except age at initial non- RP 
sign/symptom (mean ± SD 57.2 ± 12.6 versus 45 ± 10.2 years; P 
= 0.008), Scl- 70 positivity (0 versus 4 [33.3%]; P = 0.04) (n = 25); 
ILD pattern on HRCT (14 NSIP [100%] versus 10 NSIP [66.7%] 
and 5 usual interstitial pneumonia [33.3%]; P = 0.04), and cardiac 
output measured by thermodilution (mean ± SD 5.9 ± 1.8 versus 
4.8 ± 1.1; P = 0.047) (data not shown).
Cardiopulmonary characteristics of the patients 
with SSc- associated ILD and PH. All CT scans assessed for 
ILD severity were obtained a median of 2.2 months (inter quartile 
range 0.3–6.3 months) after the diagnosis of PH based on diag-
nostic RHC. Seven patients with SSc- associated ILD and PH 
(24.1%) were classified as having PAH. Six patients (20.7%) were 
classified as having WHO Group II PH; 3 of those patients had 
<20% extent of ILD on HRCT, and 3 patients had >20% extent 
of ILD on HRCT. One of the patients with WHO Group II PH with 
>20% extent of ILD on HRCT also had features of combined 
postcapillary and precapillary PH based on PCWP >15 mm Hg 
and diastolic PAP − PCWP ≥7 mm Hg according to the clas-
sification by Vachiery et al (16).  That patient also had features 
of chronic thromboembolic disease based on pulmonary artery 
angiogram (16). Sixteen patients (55.2%) were classified as hav-
ing WHO Group III PH. Ten patients (34.5%) with WHO Group III 
PH had pulmonary vascular resistance (PVR) >3.0 Wood units, 
and 4 of those patients (13.8%) were classified as having severe 
PH based on a mean PAP of ≥35 mm Hg (13) (Figure 1). Car-
diopulmonary characteristics are summarized for patients with 
SSc- associated ILD and PH in Table 2.
We also applied a previously published definition of clinically 
significant ILD, which classifies patients as having clinically signif-
icant ILD if they have >30% disease extent on HRCT, or 10–30% 
disease extent on HRCT and an FVC of <70% (17,18). Of the 29 
patients with PH in the present study, 15 (51.7%) had clinically 
significant ILD.
Treatment and outcomes of SSc- associated ILD 
and PH. Twenty- four patients (82.8%) with SSc- associated 
ILD and PH underwent ILD treatment during their SSc- 
associated ILD disease course. Eleven patients were treated 
only with mycophenolate mofetil monotherapy, 6 patients 
received mycophenolate mofetil after treatment with cyclo-
phosphamide, 2 patients participated in clinical trials and 
 transitioned to mycophenolate mofetil, and other patients 
received mycophenolate mofetil and pirfenidone (1 patient), 
cyclophosphamide followed by rituximab (1 patient), rituximab 
followed by mycophenolate mofetil and tocilizumab (1 patient), 
rituximab only (1 patient), and autologous hematopoietic stem 
cell transplantation (1 patient) (Table 3).
During their SSc- associated PH disease course, 24 
patients with SSc- associated ILD and PH (82.8%) were treated 
with PAH- specific therapies. Nine patients (31%) were treated 
with dual PAH- targeted therapy, 1 of whom was treated with 
inhaled prostacyclins and 1 of whom was treated with intrave-
nous (IV) prostacyclins. Four patients (13.8%) were treated with 
triple PAH- targeted therapy, 2 of whom were treated with inhaled 
prostacyclins and 2 of whom were treated with IV prostacyc-
lins. Five patients (17.2%) with SSc- associated ILD and PH, 3 
of whom were characterized as having WHO Group II and 2 of 
whom were characterized as having WHO Group III, were not 
prescribed PAH- specific therapies. The majority (79.2%) of the 
patients treated with PAH- specific therapies were started on 
phosphodiesterase 5 (PDE5) inhibitors alone, and the majority 
(45.8%) of the patients treated with PAH- specific therapies dur-
ing their SSc- associated PH disease course were treated with 
single- agent therapy only (Table 3).
Of the 24 patients who were treated with PAH- specific 
therapies, 7 patients had PAH, 10 patients had WHO Group 
III PH with PVR >3.0 Wood units, 1 patient had WHO Group 
II PH with >20% extent of ILD on HRCT and PVR >3.0 Wood 
units, and 1 patient had combined postcapillary and precapil-
lary PH. The remaining 5 patients had WHO Group II or Group 
III PH with PVR <3.0 and were treated with PAH therapy due 
to unexplained decline in DLco, worsening symptoms, and/
or severe WHO functional class. Twenty patients (69%) were 
receiving ILD therapies and PAH- specific therapies simulta-
neously. Adverse events due to PAH- specific therapies were 
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known side effects of the PAH- specific therapies, and no case 
of worsening ventilation/perfusion mismatch was observed 
based on chart review.
At PH diagnosis and at the time of data analysis, most 
patients had a WHO functional class of II or III. Five patients 
with SSc- associated ILD and PH, who were receiving ILD ther-
apies and PAH- specific therapies, improved by at least 1 WHO 
functional class from PH diagnosis to the time of data analy-
sis. One patient with WHO Group III PH, with  hemodynamic 
Table  2. Cardiopulmonary characteristics of the patients with 
SSc- associated ILD and PH (n = 29)*
WHO PH group, no. (%)
Group 1 7 (24.1)
Group 2 6 (20.7)
Group 3 16 (55.2)
ILD involvement on HRCT, no. (%)
>20% 19 (65.5)
<20% 10 (34.5)
PFTs (at PH diagnosis)
FVC, % predicted 70.3 ± 18.1
TLC, % predicted 84.7 ± 16.5
DLco, % predicted 43.1 ± 15.8
FVC, % predicted/DLco, % predicted 2 ± 1.5
TTE (at PH diagnosis)
RVSP, mm Hg (n = 27)† 44.9 ± 21.6
RAP, mm Hg (n = 27)† 7.9 ± 3.2
RA dilation, no. (%) 13 (44.8)
RV dilation, no. (%) 11 (37.9)
Abnormal RV function, no. (%) (n = 28) 6 (21.4)
RHC
Mean PAP, mm Hg 33.4 ± 7.2
Mean PCWP, mm Hg 13.2 ± 3.2
Mean RAP, mm Hg 9.9 ± 3.3
Cardiac output (by the Fick method) 5.3 ± 1.5
Cardiac output (by thermodilution) 5.3 ± 1.5
PVR (Wood units) 4.3 ± 3.3
Mean PAP on RHC, no. (%)
25–35 mm Hg 20 (69)
35–45 mm Hg 8 (27.6)
>45 mm Hg 1 (3.4)
PVR on RHC, no. (%)
0–6 Wood units 21 (72.4)
6–12 Wood units 7 (24.1)
>12 Wood units 1 (3.4)
* Except where indicated otherwise, values are the mean ± SD. 
WHO = World Health Organization; RAP = right atrial pressure; RA 
= right atrial; RHC = right- sided heart catheterization; PAP = pulmo-
nary arterial pressure; PCWP = pulmonary capillary wedge pres-
sure; PVR = pulmonary vascular resistance (see Table 1 for other 
definitions). 
† No tricuspid regurgitation jet was observed in 2 patients. 
Table  3. Treatment of and outcomes in patients with SSc- 
associated ILD and PH (n = 29)*
History of treatment with PAH- targeted therapies 24 (82.8)
Initial treatment with PAH- targeted therapies
None 5 (17.2)
PDE5 inhibitor 19 (65.5)
PDE5 inhibitor and ERA 4 (13.8)
IV prostacyclin 1 (3.4)
Most recent PAH- targeted therapy regimen
None 6 (20.7)
PDE5 inhibitor 13 (44.8)
ERA 1 (3.4)
PDE5 inhibitor and ERA 3 (10.3)
PDE5 inhibitor and inhaled prostacyclin 1 (3.4)
ERA and IV prostacyclin 1 (3.4)
PDE5 inhibitor, ERA, and inhaled prostacyclin 2 (6.9)
PDE5 inhibitor, ERA, and IV prostacyclin 1 (3.4)
PDE5 inhibitor, ERA, and clinical trial 1 (3.4)
Use of single- agent PAH- targeted therapy 11 (37.9)
Use of dual- agent PAH- targeted therapy 9 (31)
Use of triple- agent PAH- targeted therapy 4 (13.8)
Requirement of prostacyclin during PH therapy 6 (20.7)
History of ILD treatment 24 (82.8)
History of ILD treatment with mycophenolate mofetil 21 (72.4)
History of ILD treatment with IV pulse 
cyclophosphamide
8 (27.6)
Most recent ILD treatment
None 9 (31)
Mycophenolate mofetil 15 (51.7)
Rituximab 2 (6.9)
Tocilizumab and mycophenolate mofetil 1 (3.4)
Pirfenidone and mycophenolate mofetil 1 (3.4)
Cyclophosphamide 1 (3.4)
History of supplemental oxygen use 9 (31)




WHO functional class (prior to PH diagnosis)
Class I 0 (0)
Class II 12 (41.4)
Class III 16 (55.2)
Class IV 1 (3.4)
WHO functional class (most recent)
Class I 4 (13.8)
Class II 8 (27.6)
Class III 17 (58.6)
Class IV 0 (0)
* Values are the number (%). PAH = pulmonary arterial hyperten-
sion; PDE5 = phosphodiesterase 5; ERA = endothelin receptor an-
tagonist; IV = intravenous; WHO = World Health Organization (see 
Table 1 for other definitions). 
† Autologous hematopoietic stem cell transplantation (HSCT). 
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features of PAH with PVR >3.0, who had a PDE5 inhibitor 
and endothelin receptor antagonist (ERA) added to prior long- 
term mycophenolate mofetil therapy, improved by 2 functional 
classes from functional class III to functional class I. Sixteen 
patients with SSc- associated ILD and PH receiving PAH- 
specific therapies, 4 of whom were never treated with ILD ther-
apy, had a stable WHO functional class during their disease 
course (Figure 2).
Nine patients with SSc- associated ILD and PH (31%) received 
supplemental oxygen during their PH disease course. No patients 
with SSc- associated ILD and PH underwent heart or lung trans-
plantation during their ILD and/or PH disease course; however, 
1 patient had undergone autologous hematopoietic stem cell 
transplantation 1 year after ILD diagnosis. Two patients with SSc- 
associated ILD and PH (6.9%) died during the study. One patient 
whose cause of death was PH had WHO Group III PH and had 
been treated with cyclophosphamide followed by mycophenolate 
mofetil and was not treated with PAH- specific therapy. The other 
patient had PAH, was treated with an ERA and IV prostacyclin, 
and died of a respiratory infection.
Survival analysis. Overall, 3 patients in the entire SSc- 
associated ILD cohort died (1 of respiratory infection, 1 of PH, and 
1 of an unknown cause due to the patient being lost to follow- up). 
The survival rate 3 years after diagnosis of SSc- associated ILD for 
all patients in the cohort was 97% (survival standard error 0.03). 
Survival analysis for those with SSc- associated ILD and PH indi-
cated that after diagnosis of PH 2 patients died (1 of respiratory 
infection and the other of PH), resulting in a survival rate at 3 years 
after PH diagnosis of 91% (survival standard error 0.06); one of 
the patients with SSc- associated ILD and PH who died had clin-
ically meaningful ILD. For the entire SSc- associated ILD cohort 
and those with SSc- associated ILD and PH, Cox proportional 
hazards regression of time to death was conducted with adjust-
ment for current age and race (non- Hispanic white versus non-
white) to account for differences between the cohorts; however, 
neither of those variables were significant in either survival model.
DISCUSSION
In this study, we examined the prevalence and explored the 
clinical characteristics, pharmacologic therapies, and outcomes in 
SSc- associated ILD. Our results demonstrate that a large propor-
tion of patients with SSc- associated ILD (31.2%) have coexisting 
PH, and 37.9% and 48.3% of PH diagnoses occurred within 3 
years and 7 years, respectively, of the onset of SSc. Most patients 
with SSc- associated ILD and PH had WHO Group III PH based 
on >20% extent of ILD on HRCT (55.2%), and the majority (10 of 
16 [63%]) of those patients with WHO Group III PH had hemody-
namic features of PAH with PVR >3.0 Wood units. The group with 
Figure 2. World Health Organization functional class (FC) prior to diagnosis of pulmonary hypertension (PH) in patients with systemic sclerosis–
associated interstitial lung disease and PH and change in functional class at the time of data analysis.
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SSc- associated ILD and PH also included a significant proportion 
of African Americans, consistent with prior studies of SSc that 
have shown that African Americans have a higher incidence of 
PH, and a recent multicenter African American cohort in which a 
similar proportion of patients (18%) had RHC- proven PH (19–21). 
The majority of patients who had SSc- associated ILD and PH had 
received immunosuppressive therapy for their ILD (82.8%), and 
82.8% received PAH- specific therapy. The survival rate for those 
with SSc- associated ILD and PH 3 years after PH diagnosis was 
91%, irrespective of ILD- and/or PAH- specific therapies.
Compared to prior studies that evaluated SSc patients with 
ILD and PH, our study is unique in that it focused on a cohort of 
patients with SSc- associated ILD and assessed the prevalence 
and the clinical course of PH in a prospective fashion, which 
indicated that the coexistence of PH with SSc- associated ILD 
is not uncommon. Thus, patients with SSc- associated ILD may 
not have cardiopulmonary symptoms solely due to ILD, and may 
in fact have PH contributing to their abnormal cardiopulmonary 
symptoms and physiology. Most studies report PH prevalence 
only for PAH in patients without significant lung fibrosis, so direct 
comparison of our results with other study populations is difficult. 
Also, the high prevalence of PH in our SSc- associated ILD cohort 
may reflect some referral bias, since our institution is well known 
for its PH expertise and our adherence to the 2013 recommen-
dations for screening and detection of CTD- associated PAH in 
our population (8). Our review of the literature identified 7 origi-
nal studies of RHC- proven SSc- associated PH with and without 
ILD. Of those, 4 studies evaluated SSc- associated PH related to 
ILD (SSc- associated PH- ILD) (17,18,22,23), 2 studies evaluated 
coexisting ILD in SSc patients who were initially evaluated for 
RHC- proven PAH (24,25), and an additional study by Trad et al 
(26) evaluated a cohort of patients with dcSSc, 17% of whom 
had ILD and PAH, although some of those patients had only TTE- 
proven PAH. Thus, future studies need to focus on assessing the 
prevalence of  coexisting PH and ILD in a systematic fashion.
Although the development of PAH is largely thought to be a 
late complication in SSc, our study indicates that a large proportion 
of patients with SSc- associated ILD and PH have a diagnosis of 
PH within 5 years of SSc onset (27). Similar results were reported 
in a study by Mathai et  al (23), which demonstrated a median 
SSc disease duration of 4 years for all patients with PH, 3 years 
for patients with SSc- associated PH- ILD, and 4.5 years for those 
with SSc- associated PAH (23). Also, in a retrospective multicenter 
study by Hachulla et al, the mean ± SD SSc disease duration at 
PAH diagnosis was 6.3 ± 6.6 years, 55.1% of the patients were 
classified as having early- onset PAH based on a PAH diagnosis 
occurring within 5 years of an initial non- RP symptom, and >50% 
of the population studied had evidence of pulmonary fibrosis on 
CT as well (28). One possible explanation for the earlier diagnosis 
of PH may be the recognition and incorporation of screening algo-
rithms for PH in SSc (6,8,12). This evidence of early development 
of PH in SSc patients sheds light on a potential problem that may 
exist in the current design of SSc- associated ILD clinical trials, 
which typically recruit patients within 5–7 years of the initial SSc 
non- RP sign/symptom and do not require a diagnostic RHC to 
rule out PH as a cause of cardiopulmonary signs and symptoms.
Clinical trials evaluating PAH therapies typically exclude 
patients with clinically significant ILD and/or PH due to SSc- 
related PH- ILD; however, according to our experience and pre-
vious studies by Launay et al (22) and Mathai et al (23), patients 
with clinically significant ILD and PH receive both ILD- specific and 
PAH- specific therapies. The 5th World Symposium on Pulmonary 
Hypertension (12) has endorsed management of WHO Group III 
PH by expert centers. Their recommendations acknowledge the 
lack of evidence for the use of PAH- specific therapies for patients 
with WHO Group III PH, citing the potential for worsening gas 
exchange in ILD patients due to ventilation/perfusion mismatch. 
Despite this, our cohort and other cohorts highlight the use of 
PAH- specific therapies in these patients. However, we acknowl-
edge that differentiating WHO Group I PH from WHO Group III PH 
in this population remains a challenge, and should not be based 
upon arbitrary cutoffs involving FVC and HRCT findings (13).
Patients with SSc- associated ILD and PH may also have a 
combination of WHO Group I PH and WHO Group III PH, which 
have different disease mechanisms. PAH is a vasculopathy char-
acterized by vascular remodeling with inflammation, fibrosis, and 
thrombosis, whereas WHO Group III PH is due to vascular destruc-
tion from lung fibrosis, vasoconstriction due to chronic hypoxia, 
and/or a vasculopathy similar to that seen in PAH but “dispropor-
tionate” to what is seen in PH due to chronic lung disease (13,29). 
“Out of proportion” PH in some forms of chronic lung diseases 
has recently been defined by Seeger et al (13) as severe PH due to 
chronic lung disease with hemodynamic findings of a mean PAP 
of ≥35 mm Hg or a mean PAP of ≥25 mm Hg and a low cardiac 
index (<2.0 liters/minute/m2). As evidenced in our cohort, a large 
proportion of patients with >20% extent of ILD on HRCT actually 
have features of both PAH and WHO Group III PH, and individuals 
within this group were treated with both PAH- specific therapies 
and immunosuppression for ILD on a case- by- case basis. The 
majority of patients in our study tolerated PAH- specific therapy 
regardless of simultaneous or prior ILD treatment and had stability 
in WHO functional class and/or 6- minute walk test.
Survival for patients with coexisting PH in the setting of SSc- 
associated ILD has varied across cohorts, but despite the exis-
tence of various PAH therapies, survival overall remains poor for 
both SSc- associated PAH and SSc- associated PH- ILD, but tends 
to be worse if PH is due to ILD. However, our 91% survival rate 
3 years after PH diagnosis is higher than survival rates reported 
in studies by Launay et al (22), Le Pavec et al (17), Mathai et al 
(23), Michelfelder et al (25), and Volkmann et al (18). Based on the 
average mean PAP and PVR on RHC and use of prosta cyclins, 
patients in our SSc- associated ILD and PH cohort appear to have 
less severe PH than those in the previously mentioned studies, 
which is likely due to our aggressive PH screening, creating lead 
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time bias and improved survival rates. Our survival rates may also 
be overestimated due to our small cohort size and infrequent 
events. We also evaluated our population of patients for clinically 
significant ILD (>30% disease extent on HRCT, or 10–30% dis-
ease extent on HRCT and an FVC <70%), and found that 51.7% 
of the patients with PH (15 of 29) had clinically significant ILD. In 
comparison, the cohorts in the studies by Le Pavec et al (17) and 
Volkmann et al (18) included SSc patients with PH and clinically 
significant ILD with a total of 70 patients with a 3- year survival 
estimate of 21% and 71 patients with a 3- year survival estimate of 
50%, respectively (17,18). The 3- year survival rate of 91% in our 
SSc- associated ILD and PH cohort, with >50% of patients with 
clinically significant ILD, is likely related to inclusion of HRCT and 
implementation of the 2013 recommendations in all patients seen 
at the University of Michigan and milder PH based on hemody-
namic findings and the use of prostacyclins in our cohort (8).
Our cohort study also highlights an ongoing dilemma in the 
classification of SSc- associated PH, as there is lack of a standard 
definition of what constitutes a significant degree of ILD based 
on pulmonary physiology and/or radiographic severity to classify 
patients as having WHO Group I PH/PAH or WHO Group III PH. 
Recent data from a single- center cohort highlight the lack of spec-
ificity of FVC % predicted for the assessment of the presence and 
severity of ILD in SSc (30). Additional differences in the definition of 
clinically significant ILD are evident when evaluating 2 recent large 
clinical trials of PAH- targeted therapies. In the PAH trial evaluating 
combination therapy with ambrisentan and tadalafil and the PAH 
trial evaluating the use of selexipag, patients with moderate-to- 
severe restrictive lung disease defined as a TLC of <60–70% were 
excluded (31,32). In the cohort evaluated in the present study, 
moderate- to- severe ILD causing WHO Group III PH was defined 
using Goh’s criteria (10), with all patients with features of WHO 
Group III PH having >20% extent of ILD on HRCT. Fischer et al 
(24), Volkmann et al (18), and Le Pavec et al (17) defined SSc- 
associated PH- ILD similar to or based on Goh’s criteria. Volkman 
et al and Le Pavec et al specifically defined significant ILD as an 
extent of fibrosis of >30% of lung involvement on HRCT, or an 
extent of fibrosis of 10–30% and an FVC of <70%. Launay et al 
(22) and Mathai et  al (23) based their SSc- associated PH- ILD 
diagnosis on PFTs and HRCT findings. A consensus is urgently 
needed for the definition of significant ILD to determine whether a 
patient has SSc- associated PAH or SSc- associated PH- ILD.
Our study has many strengths. First, we studied a well- 
characterized prospective SSc- associated ILD cohort recruited 
at a single center. Second, all patients underwent screening for 
PH based on the 2013 recommendations by Khanna et al, and 
those who met the criteria underwent RHC (8). However, this 
study is not without limitations. Our results may be skewed since 
patients were recruited at a tertiary care center with highly spe-
cialized scleroderma, ILD, and PAH clinics. Like other cohorts, 
the management of PH and ILD was not standardized, which 
may have impacted the outcomes. Last, although we instituted 
a  standardized algorithm for PH screening, we may have missed 
some patients with mild PH.
Patients with SSc- associated ILD can also develop PH early 
on in their SSc disease course. These patients with ILD and PH 
often have dcSSc and often have features of WHO Group III PH 
due to their ILD but also have hemodynamic features of PAH, 
which may warrant the use of both immunosuppressive ther-
apies and PAH- specific therapies. The presence of PH early 
on in patients with SSc- associated ILD is a key factor we must 
recognize when designing clinical trials for SSc- associated ILD, 
since PH may be confounding patient- reported outcomes and 
cardiopulmonary physiology in these patients, which may affect 
the outcome of clinical trials. Future prospective studies in SSc- 
associated ILD should confirm our findings and also explore the 
impact of the new hemodynamic definition of PH, which was 
recently proposed at the 6th World Symposium on Pulmonary 
Hypertension (33,34).
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